SCHEMBL25890248

SCHEMBL25890248

CCC1(O)C(=O)N(C)c2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.68
ALDH1A1 P00352 4/20 0.58
CBX7 O95931 2/20 0.56
CDY1; CDY1B Q9Y6F8 2/20 0.56
MAPK1 P28482 2/20 0.56
CDYL2 Q8N8U2 1/20 0.56
CDYL Q9Y232 1/20 0.56
MAPT P10636 4/20 0.54
GAA P10253 2/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
RAB9A P51151 2/20 0.53
HPGD P15428 1/20 0.53
TSHR P16473 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
LMNA P02545 2/20 0.50
PKM P14618 1/20 0.49
KDM4E B2RXH2 1/20 0.49
HCRTR1 O43613 1/20 0.49
NQO1 P15559 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3201165 0.82 ALDH1A1 (0.65) RAD52ALDH1A1CBX7CDY1; CDY1BMAPK1
SCHEMBL18415222 0.81 RAD52 (1.00) RAD52ALDH1A1CBX7CDY1; CDY1BMAPK1
SCHEMBL25890527 0.80 ALDH1A1 (0.63) ALDH1A1CBX7CDY1; CDY1BCDYL2CDYL
SCHEMBL16377147 0.80 RAD52 (0.63) RAD52ALDH1A1CBX7CDY1; CDY1BMAPK1
SCHEMBL38659116 0.80 RAD52 (0.59) RAD52ALDH1A1CBX7CDY1; CDY1BMAPK1
SCHEMBL27780991 0.79 ALDH1A1 (0.59) RAD52ALDH1A1CBX7CDY1; CDY1BMAPK1
SCHEMBL2489202 0.79 HTR7 (0.56) RAD52ALDH1A1CBX7CDY1; CDY1BMAPK1
SCHEMBL28449922 0.79 ALDH1A1 (0.81) RAD52ALDH1A1CBX7CDY1; CDY1BMAPK1
SCHEMBL24281187 0.77 RAD52 (0.72) RAD52ALDH1A1CBX7CDY1; CDY1BMAPK1
SCHEMBL18189026 0.77 ALDH1A1 (0.67) RAD52ALDH1A1CBX7CDY1; CDY1BMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST RAQUALIA PHARMA INC. (JP) 2024-01-18 US disclosed
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-07-27 US disclosed
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST CRHR2, CRHR1, CRH RAD52 2416/4885ALDH1A1 4326/4885CBX7 472/4885
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP3 RAD52 240/4885ALDH1A1 426/4885CBX7 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.